- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
January 26, 2021Robins Kaplan Welcomes New Diversity and Inclusion Director
-
January 25, 2021Robins Kaplan Files U.S. Supreme Court Amicus Brief on Behalf of Former U.S. Attorneys
-
January 25, 2021David Martinez Named 2021 Minority Leader of Influence
-
January 28, 2021COVID-19: The Show Did Not Go On
-
February 9, 2021Smart Phone Privacy and Data Security – How to Assess and Minimize Risk in the Current Reality
-
March 6, 2021With Our Voices 2021 Arc Gala
-
December 27, 2020Covid-19 Relief Bill Provides Long-Awaited Funding to Small Businesses and Individuals
-
December 17. 2020Covid-19 Divorce and Marital Property Agreements
-
Fall 2020COVID Immunity: No, Not That Kind of Immunity
-
January 26, 2021Financial Daily Dose 1.26.2021 | Top Story: Apollo Global Ousts Leon Black as CEO Over Epstein Ties
-
January 25, 2021Financial Daily Dose 1.25.2021 | Top Story: Merck Abandons Covid Vaccine Effort Over Ineffective Results
-
January 22, 2021Financial Daily Dose 1.22.2021 | Top Story: Google Threatens to Pull Search From Down Under Over Proposed Law
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generics Need Sword, Shield For 'Exceptional' Patent Case
Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.
September 18, 2014
Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.
All Content © 2003‐2014, Portfolio Media, Inc.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Law360
READ FULL ARTICLE Related Professionals
Jeffrey Alan Hovden
Partner
Related Publications
December 9, 2020
November 2020
Explaining the Almost Unexplainable
David Prange, Benjamen Linden, Vivek Biswas - Intellectual Property Magazine
November 9, 2020
Hatch-Waxman Venue Is Further Narrowed
Jeffrey Alan Hovden, Haroon Mian
Fall 2020
ANDA Approvals
GENERICally Speaking Fall 2020
Fall 2020
ANDA Litigation Settlements
GENERICally Speaking Fall 2020
Related News
October 12, 2020
September 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.